Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Krishna-Prasad-Chigurupati"

25 News Found

Granules India receives ANDA approval for Trazodone Tablets
Drug Approval | August 11, 2024

Granules India receives ANDA approval for Trazodone Tablets

Trazodone tablets are indicated for the treatment of major depressive disorder in adults


Granules India posts Q1 FY25 consolidated PAT higher at Rs. 134.64 Cr
News | July 31, 2024

Granules India posts Q1 FY25 consolidated PAT higher at Rs. 134.64 Cr

Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024


Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives
News | July 22, 2024

Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives

Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23


Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
Drug Approval | April 14, 2024

Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations

This facility manufactures APIs & formulations of oncology and non-oncology products.


Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
News | January 23, 2024

Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr

Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023


Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr
News | November 13, 2023

Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr

Sales in the US region grew well, partially offset by the decline in the LATAM and European regions


Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr
News | August 10, 2023

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24


Granules India successfully completes Two US FDA Audits in a span of 2 weeks
Drug Approval | July 03, 2023

Granules India successfully completes Two US FDA Audits in a span of 2 weeks

The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.


Granules India inaugurates packaging facility in Virginia
Supply Chain | March 30, 2023

Granules India inaugurates packaging facility in Virginia

The facility is over 79,000 square feet and is equipped with packaging lines


Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
News | October 30, 2022

Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr

The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track